Elevance Health Future Growth
Future criteria checks 1/6
Elevance Health is forecast to grow earnings and revenue by 12.5% and 6.8% per annum respectively. EPS is expected to grow by 15.6% per annum. Return on equity is forecast to be 17.1% in 3 years.
Key information
12.5%
Earnings growth rate
15.6%
EPS growth rate
Healthcare earnings growth | 20.7% |
Revenue growth rate | 6.8% |
Future return on equity | 17.1% |
Analyst coverage | Good |
Last updated | 18 Dec 2024 |
Recent future growth updates
Recent updates
Returns Are Gaining Momentum At Elevance Health (NYSE:ELV)
Dec 15Elevance Health: A Quality Underpriced Stock Returning To Health
Dec 11Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Nov 30We Think Elevance Health's (NYSE:ELV) Profit Is Only A Baseline For What They Can Achieve
Oct 29Elevance Health: A Bad Q3 Was Almost Inevitable Given Industry Headwinds
Oct 17Elevance: Our Top Value Pick Trading At 12.5x Earnings And Growing At 12.5%
Oct 10Is Now An Opportune Moment To Examine Elevance Health, Inc. (NYSE:ELV)?
Oct 08Investors Continue Waiting On Sidelines For Elevance Health, Inc. (NYSE:ELV)
Sep 11Elevance Health: Strong Earnings Growth Supports Strong Dividend Growth
Sep 06There's Been No Shortage Of Growth Recently For Elevance Health's (NYSE:ELV) Returns On Capital
Aug 29Here's Why We Think Elevance Health (NYSE:ELV) Is Well Worth Watching
Aug 02Elevance Health: Healthcare Services Segment Is Gaining Traction
Jul 31Elevance Health: Buy A Dividend Growth Machine
Jul 18Elevance Health: Favorable Trends Are Emerging (Rating Upgrade)
Jun 28Is Now An Opportune Moment To Examine Elevance Health, Inc. (NYSE:ELV)?
Jun 11Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
May 27We Think Shareholders Will Probably Be Generous With Elevance Health, Inc.'s (NYSE:ELV) CEO Compensation
May 09Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63
Apr 25Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23Is Elevance Health (NYSE:ELV) Using Too Much Debt?
Apr 16Elevance Health: Not Doing Enough In 2024 To Justify Premium Price
Apr 11Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors
Apr 01Elevance: A Healthy Dose Of Dividend Growth
Mar 21Elevance Heath: Financial Growth And Technical Strength Indicate A Buy
Mar 07Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63
Feb 19Elevance Health: Time To Buy This Incredible Dividend Growth Stock
Jan 26Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement
Jan 19Is Elevance Health (NYSE:ELV) A Risky Investment?
Jan 02A Look At Elevance's Margin Dynamics
Nov 23Elevance Health: A High Conviction Defensive Blue Chip Buy
Oct 19Elevance: Pave The Way For The Next UnitedHealth
Sep 21Here's The Price I Would Buy Elevance Health Stock
Sep 13Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental
Jul 24Elevance Health: Beaten Down Share Price Offers Solid Potential
Jul 10Elevance Health: A Critical Update (Rating Downgrade)
Jun 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 200,927 | 8,559 | 8,792 | 9,164 | 12 |
12/31/2025 | 187,662 | 7,303 | 7,579 | 8,049 | 15 |
12/31/2024 | 175,114 | 6,341 | 5,032 | 5,443 | 13 |
9/30/2024 | 174,015 | 6,418 | 871 | 2,131 | N/A |
6/30/2024 | 171,719 | 6,691 | 820 | 2,067 | N/A |
3/31/2024 | 171,745 | 6,244 | 2,296 | 3,570 | N/A |
12/31/2023 | 171,340 | 5,987 | 6,765 | 8,061 | N/A |
9/30/2023 | 168,626 | 5,996 | 8,246 | 9,514 | N/A |
6/30/2023 | 165,716 | 6,310 | 10,571 | 11,825 | N/A |
3/31/2023 | 160,676 | 6,094 | 11,128 | 12,327 | N/A |
12/31/2022 | 156,599 | 5,894 | 7,247 | 8,399 | N/A |
9/30/2022 | 153,251 | 6,166 | 10,395 | 11,589 | N/A |
6/30/2022 | 149,134 | 6,072 | 8,022 | 9,169 | N/A |
3/31/2022 | 144,353 | 6,228 | 7,263 | 8,400 | N/A |
12/31/2021 | 138,643 | 6,158 | 7,277 | 8,364 | N/A |
9/30/2021 | 133,883 | 5,518 | 9,480 | 10,505 | N/A |
6/30/2021 | 129,219 | 4,231 | 5,778 | 6,851 | N/A |
3/31/2021 | 124,632 | 4,714 | 9,657 | 10,678 | N/A |
12/31/2020 | 121,868 | 4,572 | 9,667 | 10,688 | N/A |
9/30/2020 | 117,449 | 4,955 | 7,108 | 8,202 | N/A |
6/30/2020 | 112,965 | 5,916 | 9,960 | 11,019 | N/A |
3/31/2020 | 109,167 | 4,779 | 5,899 | 6,946 | N/A |
12/31/2019 | 104,212 | 4,807 | 4,984 | 6,061 | N/A |
9/30/2019 | 100,165 | 4,298 | 4,151 | 5,197 | N/A |
6/30/2019 | 96,742 | 4,074 | 3,007 | 4,137 | N/A |
3/31/2019 | 94,220 | 3,989 | 2,018 | 3,242 | N/A |
12/31/2018 | 92,091 | 3,750 | 2,619 | 3,827 | N/A |
9/30/2018 | 91,409 | 4,556 | 891 | 2,063 | N/A |
6/30/2018 | 90,584 | 4,344 | N/A | 3,861 | N/A |
3/31/2018 | 90,061 | 4,145 | N/A | 3,712 | N/A |
12/31/2017 | 90,049 | 3,843 | N/A | 4,185 | N/A |
9/30/2017 | 89,055 | 2,980 | N/A | 5,763 | N/A |
6/30/2017 | 88,038 | 2,851 | N/A | 4,322 | N/A |
3/31/2017 | 87,083 | 2,777 | N/A | 4,599 | N/A |
12/31/2016 | 84,862 | 2,470 | N/A | 3,270 | N/A |
9/30/2016 | 83,364 | 2,282 | N/A | 3,943 | N/A |
6/30/2016 | 81,866 | 2,319 | N/A | 3,322 | N/A |
3/31/2016 | 80,412 | 2,398 | N/A | 3,825 | N/A |
12/31/2015 | 79,158 | 2,560 | N/A | 4,212 | N/A |
9/30/2015 | 77,959 | 2,886 | N/A | 3,472 | N/A |
6/30/2015 | 76,605 | 2,862 | N/A | 3,734 | N/A |
3/31/2015 | 75,066 | 2,734 | N/A | 3,632 | N/A |
12/31/2014 | 73,886 | 2,560 | N/A | 3,369 | N/A |
9/30/2014 | 72,792 | 2,362 | N/A | 3,337 | N/A |
6/30/2014 | 72,090 | 2,385 | N/A | 4,129 | N/A |
3/31/2014 | 71,307 | 2,453 | N/A | 3,483 | N/A |
12/31/2013 | 71,024 | 2,634 | N/A | 3,052 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELV's forecast earnings growth (12.5% per year) is above the savings rate (2.6%).
Earnings vs Market: ELV's earnings (12.5% per year) are forecast to grow slower than the US market (15.2% per year).
High Growth Earnings: ELV's earnings are forecast to grow, but not significantly.
Revenue vs Market: ELV's revenue (6.8% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: ELV's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ELV's Return on Equity is forecast to be low in 3 years time (17.1%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/20 23:01 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Elevance Health, Inc. is covered by 52 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jasper Hellweg | Argus Research Company |
Hua Ha | Baird |
Ishan Majumdar | Baptista Research |